Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment ...

Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of distribution while simultaneously ...

Amgen is running a number of studies of its obesity drug, MariTide.

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

US biotech giant Amgen today announced the European Commission (EC) has approved Uplinza (inebilizumab) as an add-on ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...